摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-哌嗪基[4-(三氟甲基)苯基]甲酮 | 179334-12-4

中文名称
1-哌嗪基[4-(三氟甲基)苯基]甲酮
中文别名
——
英文名称
4-Trifluoromethylbenzoylpiperazine
英文别名
1-[4-(Trifluoromethyl)benzoyl]piperazine;piperazin-1-yl-[4-(trifluoromethyl)phenyl]methanone
1-哌嗪基[4-(三氟甲基)苯基]甲酮化学式
CAS
179334-12-4
化学式
C12H13F3N2O
mdl
MFCD07392818
分子量
258.243
InChiKey
QBTRUOBOJNFCSN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    356.2±42.0 °C(Predicted)
  • 密度:
    1.265±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.416
  • 拓扑面积:
    32.3
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 储存条件:
    室温

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat
    申请人:Molecular Geriatrics Corporation
    公开号:US05658909A1
    公开(公告)日:1997-08-19
    Disclosed are compounds of formula I: ##STR1## or the pharmaceutically acceptable salts thereof wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar.sub.1 and Ar.sub.2 independently represent aryl groups; and Y is hydrogen; or Y and R.sub.1 or R.sub.2 together represent CH.sub.2 ; CH.sub.2 CH.sub.2 ; CH.sub.2 O; CH.sub.2 S forming a five or six membered ring and such ring may be optionally substituted with loweralkyl or phenyl; or pharmaceutically acceptable salts thereof, useful in the treatment of neoplastic diseases, and bacterial or fungal infections, and for preventing or decreasing the production of abnormally phosphorylated paired helical filament (PHF) epitopes associated with Alzheimer's Disease and, therefore for treating Alzheimer's Disease.
    揭示了以下式I的化合物:##STR1##或其药学上可接受的盐,其中X是羰基、磺酰基、亚甲基或亚甲基,或者亚甲基上带有可选择取代的苯基;Z是氮或CH;Ar.sub.1和Ar.sub.2分别代表芳基;Y是氢;或者Y和R.sub.1或R.sub.2一起代表CH.sub.2;CH.sub.2 CH.sub.2;CH.sub.2 O;CH.sub.2 S形成五元或六元环,该环可以选择性地取代为较低的烷基或苯基;或其药学上可接受的盐,用于治疗肿瘤性疾病,细菌或真菌感染,并用于预防或减少与阿尔茨海默病相关的异常磷酸化成对螺旋丝(PHF)表位的产生,因此用于治疗阿尔茨海默病。
  • Substituted 1-aryl-3-piperazin-1'-yl propanones
    申请人:Molecular Geriatrics Corporation
    公开号:US05693804A1
    公开(公告)日:1997-12-02
    Disclosed are compounds of formula I: ##STR1## wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar.sub.1 and Ar.sub.2 independently represent aryl groups; and Y is hydrogen; or Y and R.sub.1 or R.sub.2 together represent CH.sub.2 ;CH.sub.2 CH.sub.2 ; CH.sub.2 O; CH.sub.2 S forming a five or six membered ring and such ring may be optionally substituted with loweralkyl or phenyl; or the pharmaceutically acceptable salts thereof, useful in the treatment of neoplastic diseases, and bacterial or fungal infections, and in preventing or decreasing the production of abnormally phosphorylated paired helical filament (PHF) epitopes associated with Alzheimer's Disease and, therefore, useful for treating Alzheimer's Disease.
    揭示了以下式I的化合物:##STR1## 其中X是羰基、磺酰基、亚甲基或亚甲基,或者亚甲基上带有可选择取代的苯基;Z是氮或CH;Ar.sub.1和Ar.sub.2分别代表芳基;Y是氢;或者Y和R.sub.1或R.sub.2一起代表CH.sub.2;CH.sub.2 CH.sub.2;CH.sub.2 O;CH.sub.2 S形成五元或六元环,该环可以选择性地用较低烷基或苯基取代;或其药学上可接受的盐,用于治疗肿瘤性疾病,细菌或真菌感染,并预防或减少与阿尔茨海默病相关的异常磷酸化成对螺旋丝(PHF)表位的产生,因此,用于治疗阿尔茨海默病。
  • NOVEL AZABICYCLOHEXANES
    申请人:Jain Rajseh
    公开号:US20120165320A1
    公开(公告)日:2012-06-28
    The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
    本发明涉及公式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体包括R和S异构体,多晶型,前药,代谢物,盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体,多晶型,前药,代谢物,盐或溶剂的过程。
  • Certain substituted 1-aryl-3-piperazin-1′-yl propanones
    申请人:Molecular Geriatrics Corporation
    公开号:US06214994B1
    公开(公告)日:2001-04-10
    Disclosed are compounds of formula I: wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1 and Ar2 independently represent aryl groups; and Y is hydrogen; or Y and R1 or R2 together represent CH2;CH2CH2; CH2O; CH2S forming a five or six membered ring and such ring may be optionally substituted with loweralkyl or phenyl; or the pharmaceutically acceptable salts thereof, useful in the treatment of neoplastic diseases, and bacterial or fungal infections, and in preventing or decreasing the production of abnormally phosphorylated paired helical filament (PHF) epitopes associated with Alzheimer's Disease and, therefore, useful for treating Alzheimer's Disease.
    公开的是以下式I的化合物: 其中X是羰基、磺酰基、亚甲基或与可选择取代的苯基取代的亚甲基; Z是氮或CH; Ar1和Ar2分别代表芳基; Y是氢;或Y和R1或R2一起代表CH2;CH2CH2;CH2O;CH2S,形成五元或六元环,该环可选择地取代为较低的烷基或苯基;或其药用可接受的盐,用于治疗肿瘤性疾病,细菌或真菌感染,并防止或减少与阿尔茨海默病相关的异常磷酸化成对螺旋丝表位(PHF)的产生,因此,可用于治疗阿尔茨海默病。
  • QUINOXALINE DERIVATIVES AS GPR6 MODULATORS
    申请人:ENVOY THERAPEUTICS, INC.
    公开号:US20150232469A1
    公开(公告)日:2015-08-20
    The present invention provides compounds of Formula (I): that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    本发明提供的化合物为式(I)的GPR6调节剂,因此可用于治疗可通过GPR6调节治疗的疾病,特别是治疗帕金森病、左多巴引起的运动障碍、亨廷顿病、其他运动障碍、无动力障碍以及涉及纹状体功能障碍的运动障碍、精神分裂症和药物成瘾。还提供了含有这种化合物的制药组合物以及制备这种化合物的过程。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐